1[1]Gale K E, Andersen J W, Tormey D C, et al. Hormonal treatment for metastatic breast cancer: An Eastern Cooperative Oncology Group phase Ⅲ trial comparing aminoglutethimide to tamoxifen [J]. Cancer, 1994,73:354-361
2[2]Thuerlimann B, Beretta K, Bacchi M, et al. First line fadrozole HCL(CGS 16949A) versus tamoxifen in postmenopausal patients with advanced breast cancer [J]. Ann Onco1,1996,7:471-479
3[3]Gershanovich M, Chaudri H A, Campos D, et al. Letrozole, a new aromatase inhibitor: Randomized trial comparing 0.5 mg and 2.5mg daily and aminoglutethimide in postmenopausal women with advanced breast cancer [J]. Ann Onco1,1998,9:639-645
4[4]Kaufmann M, Bajetta E, Dirix L Y, et al. Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: Results of a phase Ⅲrandomised double-blind trial [J]. J Clin Oncol,2000,18:1399-1411
5[5]Mouridsen H, Gershanovich M, Sun Y, et al. Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: Results of a phase Ⅲ study of the International Letrozole Cancer Group [J]. J Clin Oncol,2001,19:2596-2606
6[1]Sondik EJ.Breast cancer trends:incidence,mortality and survival[J]. Cancer, 1994,74: 995.
7[2]Jemal A,Thomas A,Murray T, et al. Cancer statistics,2002[J]. CA Cancer J Clin, 2002,52:23.
8[3]Howe HL,Wingo PA,Thun MJ,et al. Annual reportto the nation on the status of cancer(1973 through 1988),featuring cancers with recent increasing trends[J].J Natl Cancer lnst, 2001,93:824.
9[4]Theobald AJ.Management of advanced breast cancer with endocrine therapy:the role of the primary healthcare team[J].lnt J Clin Pract, 2000,54:665.
10[5]Jaiyesimi IA, Buzdar AU,Decker DA.Use of tamoxifen for breast cancer: twenty-eight years later [J].J Clin Oncol, 1995,13:513.
